Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Gul, S.; Ozcan, O.; Asar, S.; Okyar, A.; Baris, I.; Kavakli, I.H.
    In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials (2020), J. Biomol. Struct. Dyn., 39, 6772-6791.
    View publication on PubMedView publication on EuropePMC

Inhibitors

EC Number Inhibitors Comment Organism Structure
2.7.7.48 conivaptan binds to RNA-dependent RNA polymerase with high affinity Severe acute respiratory syndrome coronavirus 2
2.7.7.48 eltrombopag binds to RNA-dependent RNA polymerase with high affinity Severe acute respiratory syndrome coronavirus 2
2.7.7.48 ergotamine binds to RNA-dependent RNA polymerase with high affinity Severe acute respiratory syndrome coronavirus 2
2.7.7.48 tipranavir binds to RNA-dependent RNA polymerase with high affinity Severe acute respiratory syndrome coronavirus 2

Natural Substrates/ Products (Substrates)

EC Number Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
2.7.7.48 nucleoside triphosphate + RNAn Severe acute respiratory syndrome coronavirus 2
-
 diphosphate + RNAn+1
-
 ?

Organism

EC Number Organism UniProt Comment Textmining
2.7.7.48 Severe acute respiratory syndrome coronavirus 2 P0DTD1 replicase polyprotein 1ab; SARS-CoV-2
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.7.7.48 nucleoside triphosphate + RNAn
-
 Severe acute respiratory syndrome coronavirus 2 diphosphate + RNAn+1
-
 ?

Synonyms

EC Number Synonyms Comment Organism
2.7.7.48 RDRP
-
 Severe acute respiratory syndrome coronavirus 2
2.7.7.48 RNA-dependent RNA polymerase
-
 Severe acute respiratory syndrome coronavirus 2

General Information

EC Number General Information Comment Organism
2.7.7.48 drug target search for drugs that target RNA-dependent RNA polymerase (RdRp) by in silico screening of the U.S. Food and Drug Administration approved drug library. Well-tolerated and widely used drugs are selected for molecular dynamics simulations to evaluate drug-protein interactions and their persistence under physiological conditions. Eltrombopag, tipranavir, ergotamine, and conivaptan bind to the enzyme with high binding free energies Severe acute respiratory syndrome coronavirus 2